Monograph Details
|
|
Hematology
> Anemias
|
|
SOLIRIS |
| Manufacturer |
|
Alexion Pharmaceuticals, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Complement inhibitor. |
| Generic Name |
|
Eculizumab 10mg/mL; soln for IV infusion after dilution; preservative-free. |
| Indications |
|
Treatment of paroxysmal nocturnal hemoglobinuria to reduce hemolysis. |
| Children |
|
<18yrs: not recommended. |
| Adults |
|
Give by IV infusion over 35 minutes. ≥18yrs: Initially 600mg every 7 days for the first 4 weeks, followed by 900mg for the fifth dose 7 days later, then 900mg every 14 days thereafter. |
| Contraindications |
|
Unresolved serious Neisseria meningitidis infection. Individuals not vaccinated against Neisseria meningitidis. |
| Precautions |
|
Give meningococcal vaccine at least 2 weeks prior to treatment. Monitor for early signs of meningococcal or other systemic infection. Increased risk of hemolysis after treatment discontinuation; monitor for at least 8 weeks. Pregnancy (Cat.C). Nursing mothers. |
| Adverse Reactions |
|
Headache, nasopharyngitis, back pain, nausea; meningococcal infection, hypersensitivity reactions. |
| How Supplied |
|
Single-use vials (30mL)—1 |
|
|
|
|
